NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

STOK

Stoke Therapeutics Inc

Jun 30 • 04:00PM ET

11.35

Dollar change -0.28
Percentage change -2.41	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT PTCT FOLD RARE NTLA CRSP EDIT ARWR VRTX ALNY

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO DFAC DFAS

Scroll to Statements

Index	RUT	P/E	14.43	EPS (ttm)	0.79	Insider Own	16.02%	Shs Outstand	54.60M	Perf Week	-2.07%
Market Cap	619.68M	Forward P/E	-	EPS next Y	-2.90	Insider Trans	-25.95%	Shs Float	45.85M	Perf Month	16.65%
Enterprise Value	266.49M	PEG	-	EPS next Q	-0.49	Inst Own	98.76%	Short Float	26.41%	Perf Quarter	57.42%
Income	50.27M	P/S	3.25	EPS this Y	109.23%	Inst Trans	7.83%	Short Ratio	16.36	Perf Half Y	0.27%
Sales	190.91M	P/B	1.77	EPS next Y	-2007.30%	ROA	16.43%	Short Interest	12.11M	Perf YTD	2.90%
Book/sh	6.41	P/C	1.73	EPS next 5Y	-15.19%	ROE	20.50%	52W High	16.15 -29.72%	Perf Year	-12.15%
Cash/sh	6.55	P/FCF	8.95	EPS past 3/5Y	10.98% 1.74%	ROIC	14.28%	52W Low	5.35 112.15%	Perf 3Y	-18.52%
Dividend Est.	-	EV/EBITDA	6.25	Sales past 3/5Y	- -	Gross Margin	97.69%	Volatility	5.07% 4.74%	Perf 5Y	-54.22%
Dividend TTM	-	EV/Sales	1.40	EPS Y/Y TTM	134.62%	Oper. Margin	20.03%	ATR (14)	0.55	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.41	Sales Y/Y TTM	2333.50%	Profit Margin	26.33%	RSI (14)	57.41	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.41	EPS Q/Q	433.23%	SMA20	-0.15%	Beta	1.14	Target Price	23.43
Payout	-	Debt/Eq	0.01	Sales Q/Q	3661.12%	SMA50	11.52%	Rel Volume	0.69	Prev Close	11.63
Employees	128	LT Debt/Eq	0.01	Earnings	May 13 BMO	SMA200	6.73%	Avg Volume	740.18K	Price	11.35
IPO	Jun 19, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	1643.12% 439.58%	Trades		Volume	509,374	Change	-2.41%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$24
Oct-14-24	Resumed	Leerink Partners	Outperform	$18
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral	$9 → $12
Apr-26-23	Resumed	Canaccord Genuity	Buy	$24
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$22 → $9
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$30
Jan-31-22	Initiated	Jefferies	Buy	$50
Dec-03-21	Initiated	BofA Securities	Buy	$43
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight	$41
May-18-21	Initiated	UBS	Neutral	$35
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform	$58
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy	$70
Dec-11-20	Reiterated	Needham	Buy	$48 → $56
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight	$49
Sep-29-20	Resumed	JP Morgan	Neutral	$34

Show Previous Ratings

Jun-17-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-25 07:30AM	Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-16-25 09:55AM	Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet (Zacks)
May-13-25 09:50AM	Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates (Zacks) -7.56%
07:00AM	Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
06:33AM	Loading…
May-12-25 06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-01-25 12:44PM	BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut (Zacks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:28AM	Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? (Investor's Business Daily)
06:45AM	Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar (Investor's Business Daily)
Apr-28-25 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-24-25 06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-22-25 12:00PM	Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +7.08%
04:00AM	Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-01-25 04:30PM	Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -6.32% +5.94%
12:40PM	Loading…
Mar-18-25 12:40PM	Stoke Therapeutics Stock Slips as CEO Steps Down (Investopedia)
12:40PM	Stoke Therapeutics Slips as CEO Steps Down (Investopedia)
08:05AM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:05AM	Stoke CEO exits; Medicare drug price talks advance (BioPharma Dive)
07:00AM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (Business Wire)
06:58AM	Stoke Therapeutics Announces CEO Transition (Business Wire)
Mar-17-25 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-26-25 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in March (Business Wire)
Feb-19-25 06:55AM	Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment (Pharmaceutical Technology)
Feb-18-25 01:32PM	Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal (Benzinga) -9.08%
08:00AM	Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments (Business Wire)
07:25AM	Biogen buys rights to Stokes rare epilepsy drug (BioPharma Dive)
Feb-05-25 08:51AM	Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength? (Zacks)
Jan-08-25 04:30PM	Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
06:31AM	Tenvie raises $200M for brain drug R&D; Sana spikes on single patients results (BioPharma Dive)
07:00AM	Loading…
Jan-07-25 07:00AM	Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire) -15.52%
Jan-06-25 04:30PM	Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome (Business Wire)
Dec-06-24 12:00PM	Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire) +5.57%
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Dec-04-24 07:00AM	Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome (Business Wire) +12.07%
Dec-02-24 08:00AM	Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting (Business Wire)
Nov-26-24 01:56AM	An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond (Pharma Voice)
Nov-20-24 09:55AM	Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-08-24 09:55AM	Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade (Zacks)
Nov-05-24 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire)
Oct-29-24 10:01AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-12-24 06:10PM	Stoke Therapeutics assumed with an Outperform at Leerink (TipRanks)
10:18AM	Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases (Insider Monkey)
Sep-23-24 07:07PM	Skorpios Trust Reduces Stake in Stoke Therapeutics Inc (GuruFocus.com)
Sep-10-24 07:00AM	Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome (Business Wire)
Sep-04-24 08:00AM	Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer (Business Wire)
Sep-03-24 08:00AM	Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire)
08:00AM	Stoke Therapeutics to Present at Upcoming Investor Conferences in September (Business Wire)
Aug-16-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Aug-08-24 06:53AM	Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold (Clinical Trials Arena)
Aug-07-24 08:25AM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates (Business Wire)
Jul-16-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -7.19%
Jun-18-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-03-24 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in June (Business Wire) +5.88%
May-22-24 07:07PM	Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares (GuruFocus.com) -6.96%
May-17-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +15.83%
May-07-24 09:04PM	Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ... (GuruFocus.com)
10:30AM	Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating (MT Newswires)
May-06-24 11:53AM	STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:05AM	Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates (Business Wire)
Apr-29-24 10:21AM	Stoke Therapeutics Appoints Thomas Leggett CFO (MT Newswires)
08:00AM	Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer (Business Wire)
Apr-25-24 10:01AM	Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline (Zacks)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
Apr-17-24 08:00AM	Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer (Business Wire) -5.86%
Apr-04-24 04:30PM	Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire) -5.03%
Mar-27-24 11:40PM	Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering (Business Wire) +37.71%
08:50AM	Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data (Zacks)
Mar-26-24 04:07PM	Stoke Therapeutics Announces Proposed Public Offering (Business Wire) +58.31%
11:20AM	Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients (Benzinga)
07:54AM	Why Is Stoke Therapeutics (STOK) Stock Up 99% Today? (InvestorPlace)
07:49AM	Stoke shares surge on updated results for Dravet drug (BioPharma Dive)
Mar-25-24 09:53PM	STOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:10PM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
04:01PM	Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome (Business Wire)
Feb-29-24 08:50AM	Why Earnings Season Could Be Great for Stoke Therapeutics (STOK) (Zacks)
Feb-26-24 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +11.95%
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-19-24 02:31PM	Triple Threat: 3 Stocks to Buy for 3X Upside Potential (InvestorPlace)
Feb-15-24 09:55AM	Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect? (Zacks)
06:59AM	Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar? (Zacks)
Jan-17-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jan-08-24 08:00AM	Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024 (Business Wire)
Jan-04-24 04:30PM	Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-02-24 10:29AM	Why healthcare, biotech may be top plays for 2024: BTIG (Yahoo Finance Video) +11.41%
Dec-14-23 09:55AM	Wall Street Analysts Predict a 220.81% Upside in Stoke Therapeutics, Inc. (STOK): Here's What You Should Know (Zacks)
Dec-01-23 09:00AM	Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting (Business Wire)
Nov-21-23 08:00AM	Stoke Therapeutics to Present Data from the Companys Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting (Business Wire) -6.47%
Nov-09-23 05:48AM	Stoke Therapeutics Inc (STOK) Reports Q3 Financial Results and Progress in Dravet Syndrome Treatment (GuruFocus.com)
Nov-07-23 07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire) +12.53%
Oct-17-23 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -6.80%
Sep-21-23 08:00AM	Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (Business Wire) -6.53%
Sep-20-23 04:30PM	Stoke Therapeutics Appoints Ian Smith to its Board of Directors (Business Wire) -6.72%
Sep-05-23 07:00AM	Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress (Business Wire)
Aug-16-23 01:00PM	This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street (Motley Fool)

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Skorpios Trust	10% Owner	Jun 04 '25	Sale	10.20	3,000,000	30,600,000	3,906,181	Jun 06 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 03 '25	Sale	10.03	6,471	64,892	25,782	Jun 04 08:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 02 '25	Sale	10.00	1,745	17,450	32,253	Jun 04 08:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 02 '25	Sale	10.03	22,790	228,543	33,998	May 05 04:08 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '25	Sale	10.00	3,841	38,410	56,788	May 05 04:08 PM
BARUCH S. TICHO	Officer	May 01 '25	Proposed Sale	9.76	34,847	340,107		May 01 04:45 PM
LEVIN ARTHUR A	Director	Mar 31 '25	Option Exercise	0.00	1,210	0	1,210	Apr 02 04:03 PM
Kaye Edward M. MD	Director	Mar 18 '25	Sale	8.67	10,382	90,012	148,253	Mar 20 06:15 PM
Kaye Edward M. MD	Director	Mar 19 '25	Sale	8.27	8,907	73,661	139,346	Mar 20 06:15 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 18 '25	Sale	8.67	3,884	33,674	63,962	Mar 20 06:12 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '25	Sale	8.27	3,333	27,564	60,629	Mar 20 06:12 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 18 '25	Sale	8.67	2,266	19,646	33,510	Mar 20 06:05 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 19 '25	Sale	8.27	1,945	16,085	31,565	Mar 20 06:05 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 15 '25	Option Exercise	0.00	13,475	0	35,776	Mar 18 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 15 '25	Option Exercise	0.00	23,100	0	67,846	Mar 18 04:08 PM
Kaye Edward M. MD	CEO	Mar 15 '25	Option Exercise	0.00	61,750	0	158,635	Mar 18 04:07 PM
Kaye Edward M. MD	CEO	Dec 30 '24	Option Exercise	0.60	35,000	21,000	96,885	Jan 02 04:14 PM
Skorpios Trust	10% Owner	Dec 23 '24	Sale	11.50	2,000,000	23,000,000	6,906,181	Dec 27 05:13 PM
Blue Horizon Enterprise Ltd	Affiliate	Dec 23 '24	Proposed Sale	11.59	2,000,000	23,180,000		Dec 23 06:15 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 09 '24	Sale	12.99	2,586	33,596	44,746	Dec 11 04:07 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 09 '24	Sale	13.61	13,666	185,978	21,476	Dec 11 04:05 PM
Kaye Edward M. MD	CEO	Dec 09 '24	Sale	12.99	6,786	88,158	61,885	Dec 11 04:04 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 06 '24	Sale	12.78	13,945	178,182	47,332	Dec 10 07:02 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 06 '24	Sale	12.78	9,696	123,891	35,142	Dec 10 07:01 PM
Kaye Edward M. MD	CEO	Dec 06 '24	Sale	12.78	6,170	78,837	68,671	Dec 10 07:00 PM
JONATHAN ALLAN	Officer	Dec 09 '24	Proposed Sale	13.27	12,114	160,753		Dec 09 04:48 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 03 '24	Option Exercise	0.00	6,000	0	44,838	Dec 05 04:21 PM
Kaye Edward M. MD	CEO	Dec 03 '24	Option Exercise	0.00	26,500	0	75,091	Dec 05 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 03 '24	Option Exercise	0.00	10,000	0	61,277	Dec 05 04:19 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 01 '24	Option Exercise	0.00	33,927	0	38,838	Dec 03 04:14 PM
Kaye Edward M. MD	CEO	Dec 01 '24	Option Exercise	0.00	21,591	0	48,591	Dec 03 04:13 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 02 '24	Option Exercise	0.60	10,000	6,000	61,277	Dec 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 01 '24	Option Exercise	0.00	48,792	0	51,277	Dec 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 02 '24	Sale	12.07	10,000	120,698	51,277	Dec 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Nov 01 '24	Option Exercise	0.60	10,000	6,000	12,485	Nov 05 04:15 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Nov 01 '24	Sale	12.68	10,000	126,803	2,485	Nov 05 04:15 PM
BARUCH TICHO	Officer	Nov 01 '24	Proposed Sale	12.36	20,000	247,200		Nov 01 04:50 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Oct 01 '24	Option Exercise	0.60	10,000	6,000	12,485	Oct 02 04:07 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Oct 01 '24	Sale	12.06	10,000	120,648	2,485	Oct 02 04:07 PM
Skorpios Trust	10% Owner	Sep 19 '24	Sale	14.05	1,937,500	27,221,875	8,906,181	Sep 23 04:23 PM
Blue Horizon E LTD	Affiliate	Sep 19 '24	Proposed Sale	15.22	1,937,500	29,488,750		Sep 19 05:23 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Sep 03 '24	Option Exercise	0.60	10,000	6,000	12,485	Sep 05 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Sep 03 '24	Sale	14.95	10,000	149,481	2,485	Sep 05 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 01 '24	Option Exercise	0.60	10,000	6,000	12,485	Aug 05 04:09 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 01 '24	Sale	14.58	10,000	145,843	2,485	Aug 05 04:09 PM
BARUCH TICHO	Officer	Aug 01 '24	Proposed Sale	14.97	30,000	449,100		Aug 01 04:25 PM
Nash Huw M.	Chief Business Officer	Jul 02 '24	Sale	13.11	2,500	32,779	0	Jul 03 04:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

STOK

Stoke Therapeutics Inc

Upgrade your FINVIZ experience